Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL76558 | 0.84 | F10 (0.58) | PTGS2F10 | |
| SCHEMBL18630668 | 0.82 | F10 (0.54) | PTGS2F10 | |
| SCHEMBL15628319 | 0.82 | F10 (0.54) | PTGS2F10 | |
| SCHEMBL28834548 | 0.82 | F10 (0.54) | PTGS2F10 | |
| SCHEMBL15846877 | 0.82 | F10 (0.54) | PTGS2F10 | |
| SCHEMBL92872 | 0.82 | PTGS2 (0.64) | PTGS2F10 | |
| SCHEMBL19456 | 0.82 | PTGS2 (0.64) | PTGS2F10 | |
| SCHEMBL2540317 | 0.82 | F10 (0.54) | PTGS2F10 | |
| SCHEMBL28956907 | 0.82 | PTGS2 (0.67) | PTGS2F10 | |
| SCHEMBL198132 | 0.81 | PTGS2 (0.57) | PTGS2F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3190104-B1 | QUINOLINONE COMPOUND AND USE THEREOF | SUNSHINE LAKE PHARMA CO LTD (CN) | 2021-10-27 | — | — | EP | disclosed |
| US-10065928-B2 | Quinolinone compound and use thereof | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2018-09-04 | — | — | US | disclosed |
| US-20170247332-A1 | QUINOLINONE COMPOUND AND USE THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2017-08-31 | — | — | US | disclosed |
| EP-3190104-A1 | QUINOLINONE COMPOUND AND USE THEREOF | Sunshine Lake Pharma Co., Ltd. (CN) | 2017-07-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170247332-A1 | QUINOLINONE COMPOUND AND USE THEREOF | HIF1AN, HIF1A, EGLN2 | PTGS2 52/4885F10 1853/4885 |
| US-10065928-B2 | Quinolinone compound and use thereof | HIF1AN, HIF1A, EGLN2 | PTGS2 52/4885F10 1853/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.